Orchestra BioMed Holdings, Inc. Balance Sheet
OBIO|3 years of annual SEC 10-K data (FY2023-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 3 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Total Assets
$115M
FY2025
Cash
$35M
Cash and equivalents
Total Debt
N/A
FY2025
Shareholder Equity
$33M
FY2025
Orchestra BioMed Holdings, Inc. had $115M in total assets and $33M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash & Equivalents | $34.7M | $22.3M | $30.6M |
| Accounts Receivable | $95.0K | $92.0K | $99.0K |
| Inventory | $310.0K | $173.0K | $146.0K |
| Current Assets | $107.9M | $69.2M | $89.1M |
| PP&E (Net) | $1.7M | $1.4M | $1.3M |
| Total Assets | $114.9M | $76.2M | $95.2M |
| Current Liabilities | $16.7M | $16.2M | $11.2M |
| Shareholders' Equity | $33.0M | $68.0M | $52.5M |